VBL Therapeutics presents VB-111 data at ASCO
VBL Therapeutics announced that MRI data from VB-111 Phase 2 and Phase 3 studies in recurrent GBM, or rGBM, presented at the American Society of Clinical Oncology, or ASCO annual meeting, showed a survival benefit associated with objective responses to the compound and a distinct signature of VB-111 activity. The UCLA analysis compared data from VBL's Phase 2 study of VB-111, which met the primary endpoint of OS benefit with a median OS, or mOS, of 414 days, to MRI data from the treatment arm in the GLOBE Phase 3 study, which had a mOS of 6.8 months, despite similar baseline tumor volume between patient cohorts. The goal of the analysis was to investigate the difference between the trial outcomes, using quantitative radiographic tools. There was a notable difference in the regimens between the studies: in the Phase 2 study, VB-111 was administered first as a single agent therapy with bevacizumab added to VB-111 upon further progression; in contrast, the GLOBE Phase 3 study regimen included co-administration of VB-111 and bevacizumab from the start of study therapy without any VB-111 monotherapy priming period.